Relevant bibliographies by topics / Tumore renale / Books

Books on the topic 'Tumore renale'

To see the other types of publications on this topic, follow the link: Tumore renale.
Author: Grafiati
Published: 9 March 2023
Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Tumore renale.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Löhr, Eberhard, and Lutz-Dietrich Leder, eds. Renal and Adrenal Tumors. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71207-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pritchard-Jones, Kathy, and Jeffrey S. Dome, eds. Renal Tumors of Childhood. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-44003-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bukowski, Ronald M., and Andrew C. Novick, eds. Clinical Management of Renal Tumors. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-60327-149-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gorin, Michael A., and Mohamad E. Allaf, eds. Diagnosis and Surgical Management of Renal Tumors. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-92309-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Arie, Belldegrun, ed. Renal and adrenal tumors: Biology and management. New York: Oxford University Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1928-, Löhr E., Leder Lutz-Dietrich, and Ackermann R. 1941-, eds. Renal and adrenal tumors: Pathology, radiology, ultrasonography, magnetic resonance (MRI), therapy, immunology. 2nd ed. Berlin: Springer-Verlag, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schoenfeld, David Aaron. Characterizing the Mechanism of Tumor Suppression by PBRM1 in Clear Cell Renal Cell Carcinoma. [New York, N.Y.?]: [publisher not identified], 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Brouwenstijn, Nathalie. Characterization of the T-cell mediated immune response to renal cell carcinoma. [Leiden: University of Leiden], 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Frances, Flinter, Maher E. R, Saggar-Malik Anand, and Crawfurd M. d'A, eds. The genetics of renal disease. Oxford: Oxford University Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lara, Primo N., and Eric Jonasch. Kidney cancer: Principles and practice. Heidelberg: Springer-Verlag, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Hayat, M. A. Methods of Cancer Diagnosis, Therapy, and Prognosis: Ovarian Cancer, Renal Cancer, Urogenitary tract Cancer, Urinary Bladder Cancer, Cervical Uterine Cancer, Skin Cancer, Leukemia, Multiple Myeloma and Sarcoma. Dordrecht: Springer Science+Business Media B.V., 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Boyle, Artie. Six months to live: Three guys on the ultimate quest for a miracle. New York: Crossroad Pub. Company, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Chen, Jindong, ed. Renal Tumor. InTech, 2013. http://dx.doi.org/10.5772/56083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Kiyama, Ryoiti, Tetsuo Fujita, L. Leo?n, and Carolin Eva Hach. Renal Tumor. DI Press, 2022.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Renal and Adrenal Tumors. Springer Verlag, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Faddegon, Stephen, Ephrem O. Olweny, and Jeffrey A. Cadeddu. Ablative technologies for renal cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0087.

Full text
Abstract:
Nearly two-thirds of newly detected renal masses are clinical stage 1, with T1a tumours accounting for 60% of the newly detected stage 1 tumours. Guideline panels convened by the American Urological Association and the European Association of Urology recommend nephron-sparing surgery as the gold standard treatment for small renal masses, with active surveillance and thermal ablation recommended as alternative strategies in select patients. However, there is a dearth of studies directly comparing outcomes for energy-based ablation to those for traditional surgical treatments for small renal masses, and future prospective randomized trials will be invaluable in this regard. Ongoing research in renal tumour ablation targets several areas, including but not limited to achieving larger ablation sizes, decreasing morbidity, and development of novel technologies for renal tumour ablation.
APA, Harvard, Vancouver, ISO, and other styles
17

Argote-Romero, Graciela. Wilms Tumor. Edited by Kirk Lalwani, Ira Todd Cohen, Ellen Y. Choi, and Vidya T. Raman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190685157.003.0041.

Full text
Abstract:
Wilms tumor, known as well as nephroblastoma, is the most common primary malignant renal tumor in children. Over 95% of all renal tumors in patients under the age of 15 are Wilms tumors. The mean age at the time of diagnosis is 3.5 years. Wilms tumors are usually an incidental finding, a large abdominal mass discovered by a family member or pediatrician. Hematuria and hypertension can be present at the time of initial diagnosis. Up to 8% of the patients will have von Willebrand disease; therefore, all patients should have baseline coagulation studies. All patients should have either computed tomography of the abdomen and pelvis with oral and intravenous contrast or magnetic resonance imaging of the abdomen and pelvis with gadolinium. Treatment includes radical nephrectomy, chemotherapy, and, in some cases, radiotherapy. Emergency surgery is rarely. The disease-free survival rate is 86% for favorable-histology tumors and 64% for anaplastic tumors.
APA, Harvard, Vancouver, ISO, and other styles
18

Kahn, S. Lowell. Bland Lipiodol-Assisted Thermal Ablation of Renal Cell Carcinoma. Edited by S. Lowell Kahn, Bulent Arslan, and Abdulrahman Masrani. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199986071.003.0073.

Full text
Abstract:
Surgical resection of renal cell carcinoma (RCC) remains the standard of care given the excellent reported outcomes for early stage disease, with 5-year cancer-specific survival (CSS) rates of 97% for pT1a and 87% for pT1b tumors after nephrectomy. Outcomes after partial nephrectomy are equally encouraging, with 5- and 10-year CSS rates of 92% and 80%, respectively, across all stages and 96% and 90%, respectively, for tumors less than 4 cm. Transarterial embolization prior to thermal ablation for RCC is far less frequent, but it is described in the literature. To date, there are no randomized controlled studies that demonstrate a benefit of combined therapy over radiofrequency ablation (RFA) or cryoablation alone. However, lipiodol is profoundly radiopaque, and utilization prior to RFA or cryoablation may aid in the visualization of the tumor.
APA, Harvard, Vancouver, ISO, and other styles
19

Novick, Andrew, and Ronald M. Bukowski. Clinical Management of Renal Tumors. Humana Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

(Editor), Ronald M. Bukowski, and Andrew Novick (Editor), eds. Clinical Management of Renal Tumors. Humana Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

Fernandez-Gomez, Jesus M., and Jorge Garcia-Rodriguez. Renal Cell Carcinoma. Nova Science Publishers, Incorporated, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

Renal Tumors: Clinics in Laboratory Medicine. Saunders, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

Libertino, John A. Renal Cancer: Contemporary Management. Springer London, Limited, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

Libertino, John A. Renal Cancer: Contemporary Management. Springer, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
25

Libertino, John A. Renal Cancer: Contemporary Management. Springer, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
26

Libertino, John A., and Jason R. Gee. Renal Cancer: Contemporary Management. Springer, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

Libertino, John A. Renal Cancer: Contemporary Management. Springer, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

Atlas of Tumor Pathology: Tumors of the Kidney, Renal Pelvis, and Ureter (Second Series, Fascicle 12). U.S. Government Printing Office, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

Gorin, Michael A., and Mohamad E. Allaf. Diagnosis and Surgical Management of Renal Tumors. Springer, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

Pritchard-Jones, Kathy, and Jeffrey S. Dome. Renal Tumors of Childhood: Biology and Therapy. Springer, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Pritchard-Jones, Kathy, and Jeffrey Dome. Renal Tumors of Childhood: Biology and Therapy. Springer Berlin / Heidelberg, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

Pritchard-Jones, Kathy, and Jeffrey S. Dome. Renal Tumors of Childhood: Biology and Therapy. Springer London, Limited, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

(Editor), Arie Belldegrun, Alastair W. S. Ritchie (Editor), Robert A. Figlin (Editor), R. T. D. Oliver (Editor), and Edwin Darracott Vaughan (Editor), eds. Renal and Adrenal Tumors: Biology and Management. Oxford University Press, USA, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
34

Eisen, Tim. The patient with renal cell cancer. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.

Full text
Abstract:
Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor therapy results in reduction of tumour volume in around three-quarters of patients and doubles progression-free survival, but treatment is not curative. The management of side effects in patients on maintenance tyrosine-kinase inhibitors has improved in the last 3 years, although still presents difficulties which have to be actively considered.The molecular biology of renal cell carcinoma is better understood than for the majority of solid tumours. The commonest form of renal cancer, clear-cell carcinoma of the kidney, is strongly associated with mutations in the von Hippel–Lindau gene and more recently with chromatin-remodelling genes such as PBRM1. These genetic abnormalities lead to a loss of control of angiogenesis and uncontrolled proliferation of tumour cells. There is a very wide spectrum of tumour behaviour from the extremely indolent to the terribly aggressive. It is not currently known what accounts for this disparity in tumour behaviour.A number of outstanding questions are being addressed in scientific and clinical studies such as a clearer understanding of prognostic and predictive molecular biomarkers, the role of adjuvant therapy, the role of surgery in the presence of metastatic disease, how best to use our existing agents, and investigation of novel targets and therapeutic agents, especially novel immunotherapies.
APA, Harvard, Vancouver, ISO, and other styles
35

Oya, Mototsugu. Renal Cell Carcinoma: Molecular Features and Treatment Updates. Springer, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
36

Oya, Mototsugu. Renal Cell Carcinoma: Molecular Features and Treatment Updates. Springer, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
37

Oya, Mototsugu. Renal Cell Carcinoma: Molecular Features and Treatment Updates. Springer, 2017.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

Sybert, Virginia P. Tumors/Hamartomas. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190276478.003.0010.

Full text
Abstract:
Chapter 10 covers Basal Cell Nevus Syndrome, Cowden Syndrome, Cylindromatosis, Dysplastic Nevus Syndrome, Epidermal Nevus, Gardner Syndrome, Giant congenital nevocytic nevus, Hereditary Keratoacanthomas, Hereditary Leiomyomatosis and renal cell cancer, Infantile Myofibromatosis, Multiple Endocrine Neoplasia Types 1, 2A, and 2B/3, Pilomatricoma, Proteus Syndrome, Sebaceous Nevus Syndrome, and Tumoral Calcinosis. Each condition is discussed in detail, including dermatologic features, associated anomalies, histopathology, basic defect, treatment, mode of inheritance, prenatal diagnosis, and differential diagnosis.
APA, Harvard, Vancouver, ISO, and other styles
39

Connor, Thomas, and Patrick H. Maxwell. Molecular basis of renal tumour syndromes. Edited by Neil Turner. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0328.

Full text
Abstract:
Kidney cancer is among the most common adult malignancy. It accounts for over 3% of all new cases of cancer diagnosed in men and around 2% of all cancers in women in the United Kingdom. In the United States, 1 in 75 people will develop renal cancer in their lifetime and approximately one-third will have metastatic disease at presentation. Kidney cancer has a notoriously poor response to chemotherapy and radiotherapy, but treatment has evolved significantly in the past 10 years. Key to these recent developments in therapy has been a revolution in our understanding of the molecular basis of the renal tumour syndromes which are described in this chapter. Two to three per cent of cases of renal cancer are recognized as due to these syndromes, but they are likely to be recurrent, and to occur in other family members. Seven genes are currently implicated in these syndromes.
APA, Harvard, Vancouver, ISO, and other styles
40

McKinney, Thurman D. Renal Complications of Neoplasia. ABC-CLIO, LLC, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
41

Miller-Hodges, Eve, and Christopher Mitchell. The patient with Wilms tumour. Edited by Giuseppe Remuzzi. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0173_update_001.

Full text
Abstract:
Wilms tumour is the most common renal tumour in childhood. It is most commonly identified as a large abdominal mass. Treatment by surgical removal and chemotherapy, and radiotherapy in more advanced stages, is curative in most patients. Five year survival is over 90%. Survivors may be at some risk from long term complications including the effects of radiotherapy on the remaining kidney.A small minority of Wilms tumours occur in individuals with an underlying mutation in the WT1 gene. WT1 mutations may also cause developmental abnormalities of the genitourinary system, and renal disease including steroid-resistant nephrotic syndrome / focal segmental glomerulosclerosis.
APA, Harvard, Vancouver, ISO, and other styles
42

Eickenberg, U., E. Löhr, R. Ackerman, and D. Bachmann. Renal and Adrenal Tumors: Pathology, Radiology, Ultrasonography, Therapy, Immunology. Springer London, Limited, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
43

Jolly, Elaine, Andrew Fry, and Afzal Chaudhry, eds. Renal medicine. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199230457.003.0017.

Full text
Abstract:
Chapter 17 covers the basic science and clinical topics relating to ophthalmology which trainees are required to learn as part of their basic training and demonstrate in the MRCP. It covers renal basic science, pathophysiology of renal disease, the kidney as an 'endocrine' organ, renal investigations, acute kidney injury, chronic kidney disease/renal failure, renal replacement therapy, renal transplantation, haemodialysis, peritoneal dialysis, nephrotic syndrome, primary glomerular causes of nephrotic syndrome/proteinuria, rapidly progressive glomerulonephritis, IgA nephropathy, mesangiocapillary glomerulonephritis, tubulointerstitial nephritis, renal tubular disorders, urinary tract obstruction, renal stone disease, urinary tract infection in adults, renovascular disease, renal tumours, inherited renal disease, and renal disease and pregnancy.
APA, Harvard, Vancouver, ISO, and other styles
44

Davenport, Dr Andrew. Renal diseases and emergencies. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199565979.003.00011.

Full text
Abstract:
Chapter 11 discusses diseases and emergencies involving renal medicine, including investigation of the renal tract, acute kidney injury (AKI), haematuria and proteinuria, urinary tract infection (UTI), urinary tract obstruction, tumours of the renal tract, chronic kidney disease (CKD), and renal transplant patients.
APA, Harvard, Vancouver, ISO, and other styles
45

Gruenewald, Simon, and Philip Vladica. Renal transplant imaging. Edited by Jeremy R. Chapman. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0282.

Full text
Abstract:
The purpose of imaging of the transplant kidney is to assess integrity, anatomy, and function. Relatively or actually non-invasive technologies can be used to monitor for potential early post-transplant complications such as acute tubular necrosis, acute rejection, haematoma, pyelonephritis, abscess, urinoma, ureteral obstruction, vascular complications, and rarely graft torsion. The technologies also assist in the diagnosis and management of late complications such as those arising from immunosuppression, chronic rejection, lymphocoele, cyst, renal artery stenosis, urinary obstruction, and tumours. This chapter demonstrates the capacity of the various imaging modalities such as ultrasound, computed tomography, and magnetic resonance imaging, to assist in the clinical management of the renal transplant recipient.
APA, Harvard, Vancouver, ISO, and other styles
46

Bower, Mark, Louise Robinson, and Sarah Cox. Endocrine and metabolic complications of advanced cancer. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0142.

Full text
Abstract:
Cancer produces endocrine and metabolic complications in two ways. Firstly, the primary tumour or its metastases may interfere with the function of endocrine glands, kidneys, or liver by invasion or obstruction. Secondly, tumours may give rise to remote effects without local spread and these actions are termed paraneoplastic manifestations of malignancy. Generally, these paraneoplastic syndromes arise from secretion by tumours of hormones, cytokines, and growth factors, but also occur when normal cells secrete products in response to the presence of tumour. This chapter reviews the pathogenesis, epidemiology, and management of the commonest paraneoplastic endocrinopathies including hypercalcaemia, Cushing’s syndrome, the syndrome of inappropriate antidiuresis, non-islet cell tumour hypoglycaemia, enteropancreatic hormone syndromes, Carcinoid syndrome, phaeochromocytoma, gonadotrophin secretion syndromes, prolactin and oxytocin secretion, and paraneoplastic pyrexia. The chapter concludes with a brief discussion of the management of metabolic disease in the context of advanced malignancy including hyperglycaemia, thyroid dysfunction, metabolic bone disease, renal failure, liver failure, and lactic acidosis.
APA, Harvard, Vancouver, ISO, and other styles
47

Glockner, James F., Kazuhiro Kitajima, and Akira Kawashima. Magnetic resonance imaging. Edited by Christopher G. Winearls. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0015_update_001.

Full text
Abstract:
Magnetic resonance imaging (MRI) provides excellent anatomic detail and soft tissue contrast for the evaluation of patients with renal disease. MRI needs longer scan time than computed tomography (CT); however, no radiation is involved. Gadolinium-based contrast agents (GBCAs) are used to help provide additional image contrast during MRI. MRI is indicated for characterization of renal mass, staging of malignant renal neoplasms, and determination of vena cava involvement by the renal tumour. Magnetic resonance (MR) angiography is widely accepted as a non-invasive imaging work-up of renal artery stenosis. MR urography is an alternative to CT urography to assess the upper urinary tract but does not identify urinary calculi. Diffusion-weighted imaging is a functional MR technique being used to characterize parenchymal renal disease and renal tumours. Nephrogenic systemic fibrosis is a rare but debilitating and potentially life-threatening condition which has been linked to exposure of GBCAs in patients with severe renal insufficiency. The risk versus benefit must be assessed before proceeding.
APA, Harvard, Vancouver, ISO, and other styles
48

Leder, Lutz-Dietrich, R. Ackermann, Eberhard Löhr, K. D. Bachmann, and H. Behrendt. Renal and Adrenal Tumors: Pathology, Radiology, Ultrasonography, Magnetic Resonance , Therapy, Immunology. Springer London, Limited, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
49

Leder, Lutz-Dietrich, and Eberhard Lohr. Renal and Adrenal Tumors: Pathology, Radiology, Ultrasonography, Magnetic Resonance , Therapy, Immunology. Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
50

Almatar, Ashraf, and Michael A. S. Jewett. Treatment of localized renal cell cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0086.

Full text
Abstract:
The incidence of localized renal cell carcinoma (RCC) has increased due to the widespread use of abdominal imaging, often for unrelated conditions. Despite improved understanding of the natural history of slow growth in many tumours and the impact of ageing and co-morbidities on patient survival, RCC is still the most lethal of genitourinary cancers and surgery remains the mainstay of treatment. Localized RCC is defined as stages T1-2 N0 M0. The relatively safe needle core biopsy is increasingly used, especially for small renal masses (SRMs), as we now know that up to 30% are benign and that RCC subtypes differ in biology and behaviour. Radical nephrectomy, either performed by open or laparoscopic technique, is indicated for stage T2 tumours or when partial nephrectomy (PN) is not believed to be feasible.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Tumore renale' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography